Summary

Persistence Market Research has recently published an extensive report on the North America Vet Compounding Pharmacies Market, providing a detailed analysis of critical market dynamics, including drivers, trends, opportunities, and challenges. The report offers comprehensive insights into the market structure, forecasting its growth trajectory from 2024 to 2033.

Key Insights:

• Market Size (2024E): USD 1.5 Billion
• Projected Market Value (2033F): USD 3.1 Billion
• Market Growth Rate (CAGR 2024 to 2033): 8.8%

North America Vet Compounding Pharmacies Market - Report Scope:

Vet compounding pharmacies are pivotal in delivering customized medications for animals, serving both pets and livestock. These pharmacies specialize in preparing tailored formulations to meet specific patient needs, particularly when commercial drugs are inadequate or unsuitable. The market caters primarily to veterinary clinics, hospitals, and individual pet owners, offering a wide array of compounded medications such as oral, topical, and injectable formulations.

Market Growth Drivers:

The North America Vet Compounding Pharmacies Market is driven by several key factors, including the growing ownership of pets and increased expenditure on pet healthcare. Rising instances of chronic diseases in pets fuel the demand for personalized medications, boosting market growth. Technological advancements in compounding techniques and stringent quality control measures enhance the safety and effectiveness of compounded medications, further propelling market expansion. Additionally, heightened awareness of the benefits of customized treatments and the expansion of veterinary healthcare infrastructure open new avenues for market players.

Market Restraints:

Despite robust growth prospects, the North America Vet Compounding Pharmacies Market faces challenges such as regulatory compliance, reimbursement policies, and safety concerns related to compounded medications. Strict regulations governing compounding practices and quality standards impose compliance burdens on pharmacies and healthcare providers, influencing market entry barriers and operational costs. Limited reimbursement coverage and the high cost of customized formulations also hinder market penetration, particularly in emerging segments of the veterinary market. Addressing these regulatory and economic challenges necessitates collaboration between industry stakeholders and policymakers to ensure access to safe and affordable compounded medications.

Market Opportunities:

The market presents significant growth opportunities driven by innovations in technology, demographic shifts, and evolving healthcare models. Integration of digital health solutions like telemedicine platforms and electronic prescriptions enhances accessibility to compounded medications, improving treatment adherence and outcomes for pet owners. Furthermore, expanding applications of compounded medications beyond traditional veterinary use, including exotic pets and wildlife, broaden market scope and foster innovation. Strategic partnerships, investments in research and development, and introduction of user-friendly, cost-effective compounding solutions are crucial to capitalize on emerging opportunities and maintain leadership in the dynamic veterinary compounding landscape.

Key Questions Answered in the Report:

• What factors are primary drivers of growth in the North America vet compounding pharmacies market?
• Which medication types and applications are leading adoption across different veterinary settings?
• How are technological advancements reshaping the competitive landscape of the market?
• Who are the key players shaping the market, and what strategies are they employing for market relevance?
• What are the emerging trends and future prospects in the North America vet compounding pharmacies market?

Competitive Intelligence and Business Strategy:

Leading companies in the North America Vet Compounding Pharmacies Market, including Wedgewood Pharmacy, Diamondback Drugs, and Roadrunner Pharmacy, prioritize innovation, differentiation, and strategic partnerships to maintain competitiveness. These firms invest in research and development to enhance compounding solutions such as sterile injectables, transdermal medications, and flavored oral suspensions, catering to diverse clinical needs. Collaborations with veterinary clinics, hospitals, and regulatory bodies facilitate market access and adoption of advanced technologies. Additionally, focus on clinical research, evidence-based practices, and pet owner education supports market growth and enhances patient outcomes in the evolving veterinary compounding landscape.

Key Companies Profiled:

• Hoye’s Pharmacy
• Vertisis Custom Pharmacy
• Smith Caldwell Drug Store
• Sixth Avenue Medical Pharmacy
• Dougherty Pharmacy
• Triangle Compounding Pharmacy Inc.,
• Wedgewood Pharmacy
• Millers Pharmacy
• Chiron Compounding Pharmacy
• MEDS Canadian Compounding Pharmacy
• Aurora Compounding
• Pace Pharmacy
• Victoria Compounding Pharmacy
• Pratt’s Compounding Pharmacy
• People’s Choice Pharmacy

Key Segments Covered in North America Vet Compounding Pharmacies Industry Research

Product:
• CNS Agents
• Anti-Infective Agents
• Hormones and Substitutes
• Anti-inflammatory Agents

Animal Type:
• Companion Animals
• Livestock Animals

End User:
• Oral
• Injectable

Country:
• U.S.
• Canada

ページTOPに戻る

Table of Contents

1. Executive Summary
1.1. North America Market Outlook
1.2. Demand Side Trends
1.3. Supply Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions and Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Adoption Rate/Usage Analysis - Key Statistics
4.2. Value Chain Analysis
4.3. Regulatory Scenario
4.4. Product USP Analysis
4.5. PESTEL Analysis
4.6. Porter’s Analysis
4.7. Key Promotional Strategies, By Key Players
5. Market Background
5.1. Macro-Economic Factors
5.1.1. North America GDP Growth Outlook
5.1.2. North America Healthcare Outlook
5.1.3. Global Compounding Pharmacies Market Outlook
5.2. Forecast Factors - Relevance & Impact
5.2.1. Product Adoption Rate
5.2.2. Prevalence of Chronic Diseases
5.2.3. Strategic Collaborations
5.2.4. Rising Pet Adoption
5.2.5. Cost of Product
5.2.6. Treatment Regime
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. By Product
6.1.2. By Animal Type
6.1.3. By Formulations
6.1.4. By Country
6.2. 2024 Market Scenario
7. North America Vet Compounding Pharmacies Market Demand (in Value US$ Bn) Analysis 2019-2023 and Forecast, 2024-2033
7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Bn) Analysis and Forecast, 2024-2033
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. North America Vet Compounding Pharmacies Market Analysis 2019-2023 and Forecast 2024-2033, By Product
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Bn) Analysis, by Product, 2019-2023
8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Product, 2024-2033
8.3.1. CNS Agents
8.3.2. Anti-Infective Agents
8.3.3. Hormones and Substitutes
8.3.4. Anti-inflammatory Agents
8.3.5. Others
8.4. Market Attractiveness Analysis, by Product
9. North America Vet Compounding Pharmacies Market Analysis 2019-2023 and Forecast 2024-2033, By Animal Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Bn) Analysis, by Animal Type, 2019-2023
9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Animal Type, 2024-2033
9.3.1. Companion Animals
9.3.1.1. Dogs
9.3.1.2. Cats
9.3.1.3. Equine
9.3.1.4. Others
9.3.2. Livestock Animals
9.4. Market Attractiveness Analysis, by Animal Type
10. North America Vet Compounding Pharmacies Market Analysis 2019-2023 and Forecast 2024-2033, By Formulations
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Bn) Analysis, By Formulations, 2019-2023
10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast, by Formulations, 2024-2033
10.3.1. Oral
10.3.2. Injectable
10.3.3. Others
10.4. Market Attractiveness Analysis, by Formulations
11. North America Vet Compounding Pharmacies Market Analysis 2019-2023 and Forecast 2024-2033, By Country
11.1. Introduction
11.2. Historical Market Size (US$ Bn) Analysis, by Country, 2019-2023
11.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Country 2024-2033
11.3.1. U.S.
11.3.2. Canada
11.4. Market Attractiveness Analysis, by Country
12. U.S. Vet Compounding Pharmacies Market Analysis 2019-2023 and Forecast 2024-2033
12.1. Introduction
12.2. Historical Market Size (US$ Bn) Trend Analysis, by Market Taxonomy, 2019-2023
12.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
12.3.1. By Product
12.3.2. By Animal Type
12.3.3. By Formulations
12.4. Market Attractiveness Analysis
12.4.1. By Product
12.4.2. By Animal Type
12.4.3. By Formulations
13. Canada Vet Compounding Pharmacies Market Analysis 2019-2023 and Forecast 2024-2033
13.1. Introduction
13.2. Historical Market Size (US$ Bn) Trend Analysis, by Market Taxonomy, 2019-2023
13.3. Current and Future Market Value (US$ Bn) Analysis and Forecast, by Market Taxonomy, 2024-2033
13.3.1. By Product
13.3.2. By Animal Type
13.3.3. By Formulations
13.4. Market Attractiveness Analysis
13.4.1. By Product
13.4.2. By Animal Type
13.4.3. By Formulations
14. Market Structure Analysis
14.1. Market Analysis, by Tier of Companies
14.2. Market Share Analysis of Top Players
14.3. Market Concentration
14.4. Market Presence Analysis
15. Competition Analysis
15.1. Competition Dashboard
15.2. Competition Deep Dive
15.2.1. Hoye’s Pharmacy
15.2.1.1. Overview
15.2.1.2. Product Portfolio
15.2.1.3. Sales Footprint
15.2.1.4. Key Financials
15.2.1.5. SWOT Analysis
15.2.1.6. Strategy Overview
15.2.1.6.1. Marketing Strategy
15.2.1.6.2. Product Strategy
15.2.1.6.3. Channel Strategy
15.2.2. Vertisis Custom Pharmacy
15.2.2.1. Overview
15.2.2.2. Product Portfolio
15.2.2.3. Sales Footprint
15.2.2.4. Key Financials
15.2.2.5. SWOT Analysis
15.2.2.6. Strategy Overview
15.2.2.6.1. Marketing Strategy
15.2.2.6.2. Product Strategy
15.2.2.6.3. Channel Strategy
15.2.3. Smith Caldwell Drug Store
15.2.3.1. Overview
15.2.3.2. Product Portfolio
15.2.3.3. Sales Footprint
15.2.3.4. Key Financials
15.2.3.5. SWOT Analysis
15.2.3.6. Strategy Overview
15.2.3.6.1. Marketing Strategy
15.2.3.6.2. Product Strategy
15.2.3.6.3. Channel Strategy
15.2.4. Sixth Avenue Medical Pharmacy
15.2.4.1. Overview
15.2.4.2. Product Portfolio
15.2.4.3. Sales Footprint
15.2.4.4. Key Financials
15.2.4.5. SWOT Analysis
15.2.4.6. Strategy Overview
15.2.4.6.1. Marketing Strategy
15.2.4.6.2. Product Strategy
15.2.4.6.3. Channel Strategy
15.2.5. Dougherty Pharmacy
15.2.5.1. Overview
15.2.5.2. Product Portfolio
15.2.5.3. Sales Footprint
15.2.5.4. Key Financials
15.2.5.5. SWOT Analysis
15.2.5.6. Strategy Overview
15.2.5.6.1. Marketing Strategy
15.2.5.6.2. Product Strategy
15.2.5.6.3. Channel Strategy
15.2.6. Triangle Compounding Pharmacy Inc.,
15.2.6.1. Overview
15.2.6.2. Product Portfolio
15.2.6.3. Sales Footprint
15.2.6.4. Key Financials
15.2.6.5. SWOT Analysis
15.2.6.6. Strategy Overview
15.2.6.6.1. Marketing Strategy
15.2.6.6.2. Product Strategy
15.2.6.6.3. Channel Strategy
15.2.7. Wedgewood Pharmacy
15.2.7.1. Overview
15.2.7.2. Product Portfolio
15.2.7.3. Sales Footprint
15.2.7.4. Key Financials
15.2.7.5. SWOT Analysis
15.2.7.6. Strategy Overview
15.2.7.6.1. Marketing Strategy
15.2.7.6.2. Product Strategy
15.2.7.6.3. Channel Strategy
15.2.8. Millers Pharmacy
15.2.8.1. Overview
15.2.8.2. Product Portfolio
15.2.8.3. Sales Footprint
15.2.8.4. Key Financials
15.2.8.5. SWOT Analysis
15.2.8.6. Strategy Overview
15.2.8.6.1. Marketing Strategy
15.2.8.6.2. Product Strategy
15.2.8.6.3. Channel Strategy
15.2.9. Chiron Compounding Pharmacy
15.2.9.1. Overview
15.2.9.2. Product Portfolio
15.2.9.3. Sales Footprint
15.2.9.4. Key Financials
15.2.9.5. SWOT Analysis
15.2.9.6. Strategy Overview
15.2.9.6.1. Marketing Strategy
15.2.9.6.2. Product Strategy
15.2.9.6.3. Channel Strategy
15.2.10. MEDS Canadian Compounding Pharmacy
15.2.10.1. Overview
15.2.10.2. Product Portfolio
15.2.10.3. Sales Footprint
15.2.10.4. Key Financials
15.2.10.5. SWOT Analysis
15.2.10.6. Strategy Overview
15.2.10.6.1. Marketing Strategy
15.2.10.6.2. Product Strategy
15.2.10.6.3. Channel Strategy
15.2.11. Aurora Compounding
15.2.11.1. Overview
15.2.11.2. Product Portfolio
15.2.11.3. Sales Footprint
15.2.11.4. Key Financials
15.2.11.5. SWOT Analysis
15.2.11.6. Strategy Overview
15.2.11.6.1. Marketing Strategy
15.2.11.6.2. Product Strategy
15.2.11.6.3. Channel Strategy
15.2.12. Pace Pharmacy
15.2.12.1. Overview
15.2.12.2. Product Portfolio
15.2.12.3. Sales Footprint
15.2.12.4. Key Financials
15.2.12.5. SWOT Analysis
15.2.12.6. Strategy Overview
15.2.12.6.1. Marketing Strategy
15.2.12.6.2. Product Strategy
15.2.12.6.3. Channel Strategy
15.2.13. Victoria Compounding Pharmacy
15.2.13.1. Overview
15.2.13.2. Product Portfolio
15.2.13.3. Sales Footprint
15.2.13.4. Key Financials
15.2.13.5. SWOT Analysis
15.2.13.6. Strategy Overview
15.2.13.6.1. Marketing Strategy
15.2.13.6.2. Product Strategy
15.2.13.6.3. Channel Strategy
15.2.14. Pratt’s Compounding Pharmacy
15.2.14.1. Overview
15.2.14.2. Product Portfolio
15.2.14.3. Sales Footprint
15.2.14.4. Key Financials
15.2.14.5. SWOT Analysis
15.2.14.6. Strategy Overview
15.2.14.6.1. Marketing Strategy
15.2.14.6.2. Product Strategy
15.2.14.6.3. Channel Strategy
15.2.15. People’s Choice Pharmacy
15.2.15.1. Overview
15.2.15.2. Product Portfolio
15.2.15.3. Sales Footprint
15.2.15.4. Key Financials
15.2.15.5. SWOT Analysis
15.2.15.6. Strategy Overview
15.2.15.6.1. Marketing Strategy
15.2.15.6.2. Product Strategy
15.2.15.6.3. Channel Strategy
16. Assumptions and Acronyms Used
17. Research Methodology